Ayala Pharmaceuticals’ (AYLA) “Market Perform” Rating Reaffirmed at Noble Financial

Noble Financial reissued their market perform rating on shares of Ayala Pharmaceuticals (NASDAQ:AYLAGet Rating) in a research report released on Tuesday, The Fly reports.

Separately, HC Wainwright decreased their target price on Ayala Pharmaceuticals from $18.00 to $12.00 and set a buy rating for the company in a report on Tuesday, August 16th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Ayala Pharmaceuticals currently has an average rating of Moderate Buy and an average target price of $12.60.

Ayala Pharmaceuticals Stock Down 10.1 %

Shares of AYLA opened at $1.16 on Tuesday. The business’s 50-day moving average price is $1.45 and its 200-day moving average price is $2.14. Ayala Pharmaceuticals has a twelve month low of $0.70 and a twelve month high of $14.50. The stock has a market cap of $17.13 million, a PE ratio of -0.46 and a beta of 2.25.

Ayala Pharmaceuticals (NASDAQ:AYLAGet Rating) last issued its quarterly earnings data on Monday, August 15th. The company reported ($0.54) EPS for the quarter, topping the consensus estimate of ($0.65) by $0.11. Ayala Pharmaceuticals had a negative return on equity of 131.63% and a negative net margin of 1,749.29%. Analysts expect that Ayala Pharmaceuticals will post -2.33 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the stock. CSS LLC IL raised its position in shares of Ayala Pharmaceuticals by 98.7% in the 2nd quarter. CSS LLC IL now owns 64,180 shares of the company’s stock worth $70,000 after acquiring an additional 31,878 shares in the last quarter. Citadel Advisors LLC purchased a new stake in Ayala Pharmaceuticals during the 2nd quarter valued at about $148,000. Renaissance Technologies LLC purchased a new stake in Ayala Pharmaceuticals during the 2nd quarter valued at about $42,000. Finally, DLD Asset Management LP grew its stake in Ayala Pharmaceuticals by 9.2% during the 1st quarter. DLD Asset Management LP now owns 172,867 shares of the company’s stock valued at $688,000 after purchasing an additional 14,635 shares during the last quarter. 28.43% of the stock is owned by institutional investors.

Ayala Pharmaceuticals Company Profile

(Get Rating)

Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, a potent, selective, and injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations.

Read More

The Fly logo

Analyst Recommendations for Ayala Pharmaceuticals (NASDAQ:AYLA)

Receive News & Ratings for Ayala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ayala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.